ReviewKidney diseases (Basel, Switzerland)2016
Overview of the Pathogenesis of ANCA-Associated Vasculitis.
Review in Kidney diseases (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06226662 (A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody), which is not on this map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- Incidence and risk factors of venous thromboembolism in ANCA-associated vasculitis: a metaanalysis and metaregression.Clinical rheumatology · 2021Pooled it
- Residential altitude, aerosol optical depth, and diagnostic composition of biopsy-confirmed renal diseases: a single-center renal biopsy study from Yunnan, China.BMC nephrology · 2026Article
- Pediatric ANCA-Associated Vasculitis: Variable Clinical Course in a Case Series of Three Patients and Literature Review.Children (Basel, Switzerland) · 2026Article
- Myeloperoxidase promotes fibrosis by inhibiting cathepsin K to bias the lung toward ECM accumulation.bioRxiv : the preprint server for biology · 2026Article
- Immunological and clinical predicators for venous thromboembolism in ANCA-associated vasculitis patients: elevated natural killer cells and cardiac involvement.Arthritis research & therapy · 2026Article
- Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation.Kidney international reports · 2026Review
- Article
- Diagnosis of Dual c- and p-ANCA Vasculitis Following SARS-CoV-2 Infection: A Case Report.The American journal of case reports · 2026Article
- The Assessment of Disease Activity and Renal Prognosis in AAV - The Contribution of Urinary Biomarkers and Renal Biopsy.Current rheumatology reports · 2026Review
- A multispecialty consensus-based red flag checklist for the early recognition of ANCA-associated vasculitis.Frontiers in immunology · 2026Article
- Developing a prediction model for poor prognosis in MPA patients using initial admission examination results: a machine learning study from Southwest China.Frontiers in immunology · 2026Article
- M-CSF, inducing CD163 macrophages, is associated with severity and prognosis of glomerulonephritis in microscopic polyangiitis.Arthritis research & therapy · 2025Article
- Unveiling the role of oxidative stress in ANCA-associated glomerulonephritis through integrated machine learning and bioinformatics analyses.Renal failure · 2025Article
- PR3-ANCA Positive Behçet's Disease with Severe Multisystem Involvement: A Diagnostic Challenge.Diagnostics (Basel, Switzerland) · 2025Article
- Novel Treatment Paradigms: Complement Inhibition in Antineutrophil Cytoplasmic Autoantibody Vasculitis.Kidney international reports · 2025Review
- Can we cure vasculitis?Current opinion in immunology · 2025Review
- Infective endocarditis mimicking antineutrophil-cytoplasmic-antibody-associated vasculitis with glomerulonephritis: a case report.Journal of medical case reports · 2025Article
- Current Understanding of the Pathogenesis of ANCA-Associated Vasculitis and Novel Treatment Options Targeting Complement Activation.Life (Basel, Switzerland) · 2025Review
- Complement as a major mediator of ANCA vasculitis and a target for precision therapy.Expert review of clinical immunology · 2025Review
- Antineutrophil cytoplasmic antibody positivity incidence before and during COVID-19 pandemic.Rheumatology international · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntineutrophil cytoplasmic autoantibodies (ANCA) are associated with a spectrum of necrotizing vasculitis including granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited necrotizing and crescentic glomerulonephritis. Clinical observations and in vitro and in vivo experimental evidence strongly indicate that ANCA are pathogenic. SUMMARY: The etiology and pathogenesis of ANCA-associated vasculitis (AAV) are multifactorial, with contributions from genetic factors, environmental exposures, infections, characteristics of the innate and adaptive immune system, and the intensity and duration of the injury. Acute vascular inflammation is induced when resting neutrophils that have ANCA autoantigens sequestered in cytoplasmic granules are exposed to priming factors - for example, cytokines induced by infection or phlogogenic factors released by complement activation - that cause the release of ANCA antigens on the surface of neutrophils and in the microenvironment around the neutrophils. ANCA bind to these ANCA antigens, which activates neutrophils by Fcγ receptor engagement and F(ab')2 binding at the neutrophil cell surface. ANCA-activated neutrophils release factors that activate the alternative complement pathway, which generates C5a, a chemoattractant for neutrophils; C5a also primes the arriving neutrophils for activation by ANCA. Activated neutrophils adhere to and penetrate vessel walls, and they release toxic oxygen radicals and destructive enzymes that cause apoptosis and necrosis of the neutrophils as well as of the adjacent vessel wall cells and matrix. KEY MESSAGES: Patients with active AAV have ongoing asynchronous onsets of countless acute lesions, with each lesion evolving through stereotypical phases within 1 or 2 weeks. Induction of remission results in termination of new waves of acute lesions and allows all lesions to progress to scarring or resolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.